Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, Malcolm J., Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R., Gallinger, Steven, Au, Heather J., Murawa, Pawel +9 more·2007·Journal of Clinical Oncology
DOI 10.1200/jco.2006.07.9525

Cited by (1,008)

Items 201–300 of 1,008

  1. Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
    Athanassios E. Argiris, Musie S Ghebremichael, Jill Gilbert, Ju‐Whei Lee, Kamakshi Sachidanandam, Jill Kolesar, Barbara Ann Burtness, Arlene A. Forastiere · 2013 · Journal of Clinical Oncology
  2. Treatment landscape of metastatic pancreatic cancer
    Sara De Dosso, Alexander Reinhard Siebenhüner, Thomas Winder, Alexander Meisel, Ralph Fritsch, Christoforos Astaras, Petr Szturz, Markus Borner · 2021 · Cancer Treatment Reviews
  3. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
    Lukas Perkhofer, Johann Gout, Élodie Roger, Fernando Kude de Almeida, Carolina Simões, Lisa Wiesmüller, Thomas Theodor Werner Seufferlein, Alexander Kleger · 2020 · Gut
  4. Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
    Renato G Martins, Upendra Parvathaneni, Julie E. Bauman, Anand K. Sharma, Luis Estuardo Raez, Michael A. Papagikos, Furhan Yunus, Brenda F. Kurland, Keith D. Eaton, Jay Justin Liao et al. · 2013 · Journal of Clinical Oncology
  5. Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
    Mohammad Hojjat‐Farsangi · 2014 · International Journal of Molecular Sciences
  6. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board
    Rintu Thomas, Zhang Weihua · 2019 · Frontiers in Oncology
  7. Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells
    Joseph N. Contessa, Mahaveer Swaroop Bhojani, Hudson H. Freeze, Alnawaz Rehemtulla, Theodore Steven Lawrence · 2008 · Cancer Research
  8. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
    George P. Stathopoulos, Konstantinos N. Syrigos, Gerasimos Aravantinos, Aris Polyzos, Pavlos Papakotoulas, George Fountzilas, Anna Potamianou, Nikolaos Ziras, John Boukovinas, John Varthalitis et al. · 2006 · British Journal of Cancer
  9. Diagnosis and management of pancreatic cancer
    Zaheer S. Kanji, Steve Gallinger · 2013 · Canadian Medical Association Journal
  10. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
    Borad, Mitesh J., Reddy, Shantan G., Bahary, Nathan, Uronis, Hope E., Sigal, Darren, Cohn, Allen L., Schelman, William R., Stephenson, Joe, Chiorean, E. Gabriela, Rosen, Peter J. et al. · 2015 · Journal of Clinical Oncology
  11. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments
    Anna I. Astashkina, David W. Grainger · 2014 · Advanced Drug Delivery Reviews
  12. New biomarkers and targets in pancreatic cancer and their application to treatment
    Eithne Costello, William Greenhalf, John P. Neoptolemos · 2012 · Nature Reviews Gastroenterology & Hepatology
  13. Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience
    Maria Clemence Schwaederle, Barbara A. Parker, Richard B. Schwab, Paul Timothy Fanta, Sarah G Boles, Gregory A. Daniels, Lyudmila A. Bazhenova, Rupa Subramanian, Alice Coutinho, Haydee Ojeda‐Fournier et al. · 2014 · The Oncologist
  14. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
    SCHLINGENSIEPEN, K, SCHLINGENSIEPEN, R, STEINBRECHER, A, HAU, P, BOGDAHN, U, FISCHERBLASS, B, JACHIMCZAK, P · 2006 · Cytokine & Growth Factor Reviews
  15. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)
    Cindy Neuzillet, Sébastien Gaujoux, Nicolas Williet, Jean‐Baptiste Bachet, Lucile Bauguion, Laurianne Colson Durand, Thierry Conroy, Laëtitia Dahan, Marine Gilabert, F. Huguet et al. · 2018 · Digestive and Liver Disease
  16. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
    Hedy Lee Kindler, Donald Richards, Lawrence E. Garbo, Edward B. Garon, Joe Stephenson, Caio Rocha‐Lima, Howard P. Safran, D. Chan, Darren M. Kocs, Francesco Galimi et al. · 2012 · Annals of Oncology
  17. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
    Elizabeth A. Buck, Alexandra Eyzaguirre, Sharon M. Barr, Stuart D. Thompson, Regina Sennello, David Young, Kenneth K. Iwata, Neil W. Gibson, Pablo J. Cagnoni, John D. Haley · 2007 · Molecular Cancer Therapeutics
  18. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
    Erik S. Knudsen, Paris J. Vail, Uthra Balaji, Hoai Ngo, Ihab W. Botros, Vladimir Makarov, Nadeem Riaz, Vinod P. Balachandran, Steven D. Leach, Debrah M. Thompson et al. · 2017 · Clinical Cancer Research
  19. Targeting cancer stem cells by curcumin and clinical applications
    Yanyan Li, Tao Zhang · 2014 · Cancer Letters
  20. Small molecule inhibitors targeting the cancers
    Guihong Liu, Tao Chen, Xin Zhang, Xuelei Ma, Shi H · 2022 · MedComm
  21. Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
    Gur Pines, Wolfgang J. Köstler, Yosef Yarden · 2010 · FEBS Letters
  22. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
    Jan Harder, Gabriele Ihorst, Volker Heinemann, Ralf‐Dieter Hofheinz, Markus Hermann Moehler, Peter Buechler, Günter Kloeppel, Christoph Röcken, Michael Bitzer, Stefan Hubert Boeck et al. · 2012 · British Journal of Cancer
  23. Nontoxic radioactive Listeria at is a highly effective therapy against metastatic pancreatic cancer
    Wilber Quispe‐Tintaya, Dinesh Chandra, Arthee Jahangir, Matthew Harris, Arturo Casadevall, Ekaterina Dadachova, Claudia Gravekamp · 2013 · Proceedings of the National Academy of Sciences
  24. Current standards and new innovative approaches for treatment of pancreatic cancer
    Thierry Conroy, Jean‐Baptiste Bachet, Ahmet Ayav, F. Huguet, Aurélien Lambert, Caroline Caramella, Raphaël Maréchal, Jean‐Luc Van Laethem, Michel Pierre Ducreux · 2016 · European Journal of Cancer
  25. KRAS-related proteins in pancreatic cancer
    Karen M. Mann, Haoqiang Ying, Joseph M. Juan, Nancy A. Jenkins, Neal G. Copeland · 2016 · Pharmacology & Therapeutics
  26. Onivyde for the therapy of multiple solid tumors
    Haijun Zhang · 2016 · OncoTargets and Therapy
  27. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
    Philippe R Rougier, Hanno B. Riess, Robert Manges, Petr Karásek, Yves Humblet, C. Barone, Armando Santoro, Sylvie Assadourian, Laurence Hatteville, Philip A. Philip · 2013 · European Journal of Cancer
  28. Desmoplasia and Chemoresistance in Pancreatic Cancer
    Marvin Schober, Ralf Jesenofsky, R. Faissner, Cornelius Weidenauer, Wolfgang Hagmann, Patrick Michl, Rainer Lothar Heuchel, Stephan Haas, Matthias J. Löhr · 2014 · Cancers
  29. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
    Chung, Vincent, McDonough, Shannon, Philip, Philip A., Cardin, Dana, Wang-Gillam, Andrea, Hui, Laifong, Tejani, Mohamedtaki A., Seery, Tara E., Dy, Irene A., Al Baghdadi, Tareq et al. · 2017 · JAMA Oncology
  30. Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology
    Margaret A. Tempero, Stephen W. Behrman, Edgar Ben‐Josef, Al B. Benson, John L. Cameron, Ephraim S. Casper, John Parker Hoffman, Richard C. Karl, Paula Kim, Wui‐Jin Koh et al. · 2005 · Journal of the National Comprehensive Cancer Network
  31. Cellular responses to EGFR inhibitors and their relevance to cancer therapy
    Pinaki R Dutta, Amit M. Maity · 2007 · Cancer Letters
  32. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging
    Willemieke S. F. J. Tummers, Sarah E. Miller, Nutte Tarn Teraphongphom, Adam J. Gomez, Idan Steinberg, David M. Huland, Steve Hong, Sri‐Rajasekhar Kothapalli, Alifia Hasan, Robert D. Ertsey et al. · 2018 · Annals of Surgical Oncology
  33. Genetically engineered mouse models of pancreatic adenocarcinoma
    Carmen E. Guerra, Mariano Barbacid · 2013 · Molecular Oncology
  34. Models for prevention and treatment of cancer: Problems vs promises
    Bharat Bhushan Aggarwal, Divya Danda, Shan R. Gupta, Prashasnika Gehlot · 2009 · Biochemical Pharmacology
  35. FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
    Lysiane Marthey, António Sá Cunha, Jean‐Frédéric Blanc, Mélanie Gauthier, Adele Cueff, Éric François, Isabelle Trouilloud, David Malka, Jean‐Baptiste Bachet, Romain Coriat et al. · 2014 · Annals of Surgical Oncology
  36. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis
    Michael Tachezy, Florian Gebauer, M. Janot, Waldemar H. Uhl, Alessandro Zerbi, Marco Montorsi, Julie Périnel, Mustapha Adham, Christos Dervenis, Christos Agalianos et al. · 2016 · Surgery
  37. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours
    Marc‐Eric Halatsch, Ursula I. Schmidt, Julianne Behnke‐Mursch, Andreas Wilhelm Unterberg, Christian Rainer Wirtz · 2006 · Cancer Treatment Reviews
  38. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
    Alison M. Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J. Sisso, Marissa S. Mattar, Allan J.W. Lui, Morana Vojnic, Sara H. Shameem, Thrusha Chauhan et al. · 2022 · Cancer Discovery
  39. What We Have Learned About Pancreatic Cancer From Mouse Models
    Pedro Antonio Pérez-Mancera, Carmen E. Guerra, Mariano Barbacid, David A. Tuveson · 2012 · Gastroenterology
  40. Pancreatic cancer: advances in treatment.
    Somala Mohammed, George Van Buren, William E. Fisher · 2014 · PubMed Central
  41. Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine
    Yousuke Nakai, Hiroyuki Isayama, Hideaki Ijichi, Takashi Sasaki, Naoki Sasahira, Kenji Hirano, Hirofumi Kogure, Kazumichi Kawakubo, Hiroshi Yagioka, Yoko Yashima et al. · 2010 · British Journal of Cancer
  42. Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer
    Stefan Hubert Boeck, P Stieber, Stefan Holdenrieder, Ralf Wilkowski, Volker Heinemann · 2006 · Oncology
  43. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer
    Satoshi Nishiwada, Masayuki Sho, Satoshi Yasuda, Keiji Shimada, Ichiro Yamato, Takahiro Akahori, Shoichi Kinoshita, Minako Nagai, Noboru Konishi, Yoshiyuki Nakajima · 2015 · Journal of Experimental & Clinical Cancer Research
  44. Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
    Axel F. Grothey, Eric E. Hedrick, ROBERT D. MASS, Somnath Sarkar, Sam Suzuki, Ramesh K. Ramanathan, Herbert I. Hurwitz, Richard M. Goldberg, Daniel J. Sargent · 2008 · Journal of Clinical Oncology
  45. Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer
    Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Tatsuya Ioka, Junji Furuse, Shinichi Ohkawa, Hiroyuki Isayama, Narikazu Boku · 2014 · Cancer Science
  46. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site
    Hidetoshi Hayashi, Takayasu Kurata, Yuichi Takiguchi, Makoto Arai, Koji Takeda, Kohei Akiyoshi, Koji Matsumoto, Takuma Onoe, Hirofumi Mukai, Nobuaki Matsubara et al. · 2019 · Journal of Clinical Oncology
  47. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
    Javle, Milind M, Shroff, Rachna T, Xiong, Henry, Varadhachary, Gauri A, Fogelman, David, Reddy, Shrikanth A, Davis, Darren, Zhang, Yujian, Wolff, Robert A, Abbruzzese, James L · 2010 · BMC Cancer
  48. The paradoxical functions of EGFR during breast cancer progression
    Remah Ali, Michael K. Wendt · 2017 · Signal Transduction and Targeted Therapy
  49. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
    Changhoon Yoo, J Y Hwang, Je Hyeong Kim, T W Kim, J S Lee, D H Park, S K Lee, Dong Wan Seo, S S Lee, MH Kim et al. · 2009 · British Journal of Cancer
  50. Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Stefano Cascinu, Massimo Falconi, Vincenzo Valentini, Svetislav Jelić · 2010 · Annals of Oncology
  51. The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
    Saroj Niraula, Boštjan Šeruga, Alberto Ocaña, Tiffany Shao, Robyn Goldstein, Ian F. Tannock, Eitan Amir · 2012 · Journal of Clinical Oncology
  52. Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer
    Hidenori Takahashi, Hiroaki Ohigashi, Kunihito Gotoh, Shigeru Marubashi, Terumasa Yamada, Masayuki Murata, Tatsuya Ioka, Hiroyuki Uehara, Masahiko Yano, Osamu Ishikawa · 2013 · Annals of Surgery
  53. Pancreatic Adenocarcinoma
    Margaret A. Tempero, J. Pablo Arnoletti, Stephen W. Behrman, Edgar Ben‐Josef, Al B. Benson, Jordan D. Berlin, John L. Cameron, Ephraim S. Casper, Steven J. Cohen, Michelle Duff et al. · 2010 · Journal of the National Comprehensive Cancer Network
  54. Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
    Matthew H. Kulke, Lawrence Scott Blaszkowsky, David P. Ryan, Jeffrey William Clark, Jeffrey A. Meyerhardt, Andrew Xiuxuan Zhu, Peter C. Enzinger, Eunice Lee Kwak, Alona Muzikansky, Colleen E. Lawrence et al. · 2007 · Journal of Clinical Oncology
  55. Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor
    Dongping Wei, Hua Li, Jie Yu, Jonathan T. Sebolt, Lili Zhao, Theodore Steven Lawrence, Peter G. Smith, Meredith Ann Morgan, Yi Sun · 2011 · Cancer Research
  56. EGFR, HER2 and VEGF Pathways
    Michael F. Press, Heinz‐Josef Lenz · 2007 · Drugs
  57. Targeted therapies for non-small cell lung cancer
    Wolfram C. M. Dempke, Tamás Sütö, Martin Reck · 2009 · Lung Cancer
  58. Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo
    Shuangjia Wang, Yue Gao, Hua Chen, Rui Kong, Hongchi Jiang, Shangha Pan, Dongbo Xue, Xuewei Bai, Bei Sun · 2010 · Cancer Letters
  59. Management of pancreatic cancer in the elderly
    Oliver Higuera · 2016 · World Journal of Gastroenterology
  60. Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy
    Davendra P. S. Sohal, Richard Matthew Walsh, Ramesh K. Ramanathan, Alok A. Khorana · 2014 · JNCI Journal of the National Cancer Institute
  61. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
    Jill Wykosky, Tim R. Fenton, Frank B. Furnari, Webster K. Cavenee · 2011 · 癌症：英文版
  62. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
    Hideki Ueno, Masafumi Ikeda, Makoto Ueno, Nobumasa Mizuno, Tatsuya Ioka, Yasushi Omuro, Takako Eguchi Nakajima, Junji Furuse · 2016 · Cancer Chemotherapy and Pharmacology
  63. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors
    Birgit Geoerger, Darren R. Hargrave, Fabienne Thomas, A. Ndiaye, Didier Frappaz, Felipe Da Matta Andreiuolo, Pascale Varlet, Isabelle Aerts, Riccardo Riccardi, Timothy Jaspan et al. · 2010 · Neuro-Oncology
  64. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
    Yoshiki Hirooka, Hideki Kasuya, Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Itzel Bustos Villalobos, Yoshinori Naoe, Toru Ichinose, Nobuto Koyama, Maki Tanaka et al. · 2018 · BMC Cancer
  65. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application
    Shuai Wang, Xiaohan Yuan, Saiqi Wang, Wen He Zhao, Xiaobing Chen, Bin Yu · 2021 · European Journal of Medicinal Chemistry
  66. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer
    Desmond Yip, Christos Stelios Karapetis, Andrew H. Strickland, Christopher Steer, David Goldstein · 2006 · Cochrane Database of Systematic Reviews · Retracted
  67. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer
    Gilda da Cunha Santos, Neesha C. Dhani, Dongsheng Tu, Kayu Chin, Olga Ludkovski, Suzanne Kamel‐Reid, Jeremy Andrew Squire, Wendy R. Parulekar, Malcolm J. Moore, Ming‐Sound Tsao · 2010 · Cancer
  68. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines
    Huanwen Wu, Liang Zhiyong, Shi Xiaohua, Ren Xinyu, Kai Wang, Liu Tonghua · 2009 · Molecular Cancer
  69. Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Hongbing Liu, Ying Wu, Tangfeng Lv, Yan-wen Yao, Yongying Xiao, Dongmei Yuan, Yong Song · 2013 · PLoS ONE
  70. Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas
    Eunice Lee Kwak, Janusz A. Jankowski, Sarah P. Thayer, Gregory Yves Lauwers, Brian W. Brannigan, Patricia L. Harris, Ross A. Okimoto, Sara M. Haserlat, David R. Driscoll, David Raymond Ferry et al. · 2006 · Clinical Cancer Research
  71. Current concepts and novel targets in advanced pancreatic cancer
    Patrick Michl, Thomas Mathias Gress · 2012 · Gut
  72. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions
    Karam, A., Ledermann, J.A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R.A., Nam, B.-H., Bacon, M. et al. · 2017 · Annals of Oncology
  73. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5‐fluorouracil, and cisplatin followed by radiotherapy and 5‐fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma
    Jerome Carl Landry, Paul J. Catalano, Charles A. Staley, Wayne Bernard Harris, John Hoffman, Marina Talamonti, Natalie Xu, Harry S. Cooper, Al B. Benson · 2010 · Journal of Surgical Oncology
  74. Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
    Marcus O. Quinkler, Stefanie Hahner, Sebastian Wortmann, Sarah Johanssen, Patrick Adam, Christian Ritte, Christian Joseph Strasburger, Bruno Allolio, Martin Faßnacht · 2008 · The Journal of Clinical Endocrinology & Metabolism
  75. Effects of Thymoquinone in the Expression of Mucin 4 in Pancreatic Cancer Cells: Implications for the Development of Novel Cancer Therapies
    María P. Torres, Moorthy Palanimuthu Ponnusamy, Subhankar Chakraborty, Lynette M. Smith, Srustidhar Das, Hwyda A. Arafat, Surinder K. Batra · 2010 · Molecular Cancer Therapeutics
  76. Current and future therapies for advanced pancreatic cancer
    Rohan Gupta, Idoroenyi Usua Amanam, Vincent M. Chung · 2017 · Journal of Surgical Oncology
  77. High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study
    Kishore Polireddy, Ruochen Dong, Gregory A. Reed, Jun Yu, Ping Chen, Stephen K. Williamson, Pierre-Christian Violet, Ziyan Yuan Pessetto, Andrew K. Godwin, Fang Fan et al. · 2017 · Scientific Reports
  78. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications
    Hu, Hai-feng, Ye, Zeng, Qin, Yi, Xu, Xiao-wu, Yu, Xian-jun, Zhuo, Qi-feng, Ji, Shun-rong · 2021 · Acta Pharmacologica Sinica
  79. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study
    Joel Randolph Hecht, J Farrell, Neil N. Senzer, John J. Nemunaitis, Alexander Rosemurgy, Theodore Chung, Nader N Hanna, Kenneth J. Chang, Milind M. Javle, Mitchell C. Posner et al. · 2012 · Gastrointestinal Endoscopy
  80. Impact of <i>KRAS</i> Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
    Kim, Seung Tae, Lim, Do Hyoung, Jang, Kee-Taek, Lim, Taekyu, Lee, Jeeyun, Choi, Yoon-La, Jang, Hye-Lim, Yi, Jun Ho, Baek, Kyung Kee, Park, Se Hoon et al. · 2011 · Molecular Cancer Therapeutics
  81. Current and Emerging Therapies in Metastatic Pancreatic Cancer
    Manji, Gulam Abbas, Olive, Kenneth P., Saenger, Yvonne M., Oberstein, Paul · 2017 · Clinical Cancer Research
  82. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
    Maura N. Dickler, Melody Cobleigh, Kathy D. Miller, Pamela M. Klein, Eric P. Winer · 2008 · Breast Cancer Research and Treatment
  83. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
    Everardo Delforge Saad, Artur Katz, Paulo M. Hoff, Marc E Buyse · 2009 · Annals of Oncology
  84. Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
    Brinda Alagesan, Gianmarco Contino, Alexander R. Guimarães, Ryan Bruce Corcoran, Vikram Deshpande, Gregory R. Wojtkiewicz, Aram F. Hezel, Kwok‐Kin Wong, Massimo F. Loda, Ralph Weissleder et al. · 2014 · Clinical Cancer Research
  85. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients
    Cheng He, Chen Liu, Jiahao Jiang, Guopei Luo, Lu Yu, Kaizhou Jin, Meng Guo, Zhenzhen Zhang, Jin Xu, Liang Liu et al. · 2017 · International Journal of Cancer
  86. Targeting cell signaling pathways for drug discovery: An old lock needs a new key
    Bharat Bhushan Aggarwal, Gautam Sethi, Veera Baladandayuthapani, Sunil Krishnan, Shishir Shishodia · 2007 · Journal of Cellular Biochemistry
  87. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
    Shaocong Wu, Liwu Fu · 2018 · Molecular Cancer
  88. Barriers and opportunities for gemcitabine in pancreatic cancer therapy
    Beutel, Alica K., Halbrook, Christopher J. · 2023 · American Journal of Physiology-Cell Physiology
  89. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer
    Henry Q. Xiong, Gauri Rajani Varadhachary, J. C. Blais, Kenneth R. Hess, James L. Abbruzzese, Robert A. Wolff · 2008 · Cancer
  90. Targeting apoptosis pathways in pancreatic cancer
    Alexander Arlt, Susanne Sebens Müerköster, H. Schäfer · 2010 · Cancer Letters
  91. S3-Leitlinie „Exokrines Pankreaskarzinom” 2007
    G. Adler, T Seufferlein, Sven Bischoff, H.–J. Brambs, Stefan Feuerbach, Gerhard G. Grabenbauer, Stephan A. Hahn, Volker Heinemann, W. Hohenberger, Jan Michael Langrehr et al. · 2007 · Zeitschrift für Gastroenterologie
  92. Perspectives in the treatment of pancreatic adenocarcinoma
    Angel Cid Arregui · 2015 · World Journal of Gastroenterology
  93. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
    Krishna Soujanya Gunturu, Xiaopan Yao, Xiangyu Cong, Jaykumar Ranchodbhai Thumar, Howard S. Höchster, Stacey Stein, Jill Lacy · 2012 · Medical Oncology
  94. Ocular Toxicity of Targeted Therapies
    Renouf, Daniel J., Velazquez-Martin, Juan P., Simpson, Rand, Siu, Lillian L., Bedard, Philippe L. · 2012 · Journal of Clinical Oncology
  95. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer
    Tianjiao Ji, Suping Li, Yinlong Zhang, Jiayan Lang, Yanping Ding, Xiao Ling Zhao, Ruifang Zhao, Yiye Li, Jian Ying Shi, Jihui Hao et al. · 2016 · ACS Applied Materials & Interfaces
  96. Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells
    Prajakta Kulkarni, Manas K. Haldar, Seungyong You, Yongki Choi, Sanku Mallik · 2016 · Biomacromolecules
  97. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy
    Michael Haas, Volker Heinemann, Frank Kullmann, Rüdiger Paul Laubender, Christina Klose, Christiane J. Bruns, Stefan Holdenrieder, Dominik Paul Modest, Christoph Udo Schulz, Stefan Hubert Boeck · 2013 · Journal of Cancer Research and Clinical Oncology
  98. Transforming growth factor‐beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
    Karl‐Hermann Schlingensiepen, Frank Jaschinski, Sven Arke Lang, Christian Moser, Edward Kenneth Geissler, Hans Jürgen Schlitt, M. Kielmanowicz, Anneliese Schneider · 2011 · Cancer Science
  99. Molecular‐targeted agents combination therapy for cancer: Developments and potentials
    Feifei Li, Changqi Zhao, Lili Wang · 2013 · International Journal of Cancer
  100. Managing Treatment-Related Adverse Events Associated with egfr Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer
    Vera Hirsh · 2011 · Current Oncology